secwatch.observer — SEC 8-K summary
======================================

Issuer:     Glucotrack, Inc. (GCTK)
CIK:        0001506983
Form:       8-K
Filed at:   2024-06-20T23:59:59+00:00
Accession:  0001493152-24-024427
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glucotrack appoints Andy Balo (ex-Dexcom EVP) to board; bylaws amended to lower quorum to one-third
--------------------------------------------------------------------------------

- Appointed Andrew K. Balo, former Dexcom EVP of Clinical & Global Access, to board as independent director, effective June 14, 2024.
- Balo brings 22 years at Dexcom, expertise in glucose monitoring regulatory submissions and clinical trials.
- Board also amended bylaws to reduce shareholder quorum requirement from majority to one-third.
- Balo will assist with upcoming human clinical studies for Glucotrack's implantable continuous blood glucose monitor.
- Balo played critical role at Dexcom; his regulatory knowledge expected to aid Glucotrack's CBGM development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506983/000149315224024427/0001493152-24-024427-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506983/000149315224024427/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-024427

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer